• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Global Biosciences Co. Selects ValGenesis VLMS

    Eisai Appoints Chief Clinical Officer of Oncology Biz

    Nexelis Acquires GSK Vax Lab in Marburg

    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal

    NovaQuest Private Equity Acquires CoreRx
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Adare Pharma Solutions

    PCI Pharma Services

    Cytovance Biologics

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Emergent BioSolutions

    Alcami

    Aphena Pharma Solutions

    Flow Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    HPAPI Drug Manufacturing Trends

    Managing accelerated timelines in manufacturing high-potency drugs.

    HPAPI Drug Manufacturing Trends
    Maurits Janssen, Head of Commercial Development, Lonza Pharma & Biotech05.05.20
    Highly potent API (HPAPI) drugs make up a growing percentage of the small molecule drug development pipeline and this group of products is growing faster than the overall small molecule segment,1 largely due to their usefulness in cancer treatments. Many of these drugs have accelerated timelines for approval and commercial development, which can be challenging for drug developers to keep up with.

    On the front-end, new technologies such as in-silico prediction tools contribute to shortening candidate selection,2 while Artificial Intelligence (AI) has already brought a first candidate into clinical development.3 On the back-end, regulatory drug approval timelines are being increasingly shortened: when analyzing drug approvals in 2019, almost three-quarters of drugs approved (71%) were approved under Priority Review.4

    A related trend is increasing competition in the oncology field, with 80% of new IND’s now belonging to small, emerging or virtual biotech companies.5 These firms often lack the manufacturing resources, capabilities and experience to effectively develop a HPAPI product for clinical trials and, if successful, on to commercial production. As such, these companies tend to outsource development, clinical and commercial manufacturing to established contract development & manufacturing organization (CDMO) partners.

    It is critical that biopharma companies ensure timely availability of sufficient drug product for clinical trials, so that clinical products are available in time for patients as soon as they are identified. If not, a patient may be treated with a different (i.e., competing) product, thus excluding that patient from the trial since patients cannot be treated with alternative products during their involvement in an ongoing clinical trial. Thus, the ability to rapidly manufacture and scale up are critical for bringing HPAPI drugs to clinic and to market at the most optimal timeline possible, while gaps in those capabilities may lead to lengthened development timelines.

    Taking these clinical dynamics into account, it becomes immediately clear that to benefit from a breakthrough indication or accelerated approval pathway, the clinical supply challenge must be addressed. What can company leaders—especially those of small or virtual companies—do to manage shortened timelines for their HPAPI products? One answer lies in the outsourcing decision and choosing a CDMO partner that can help rapidly progress HPAPI compounds to clinical or commercial development. When it comes to managing accelerated timelines for HPAPI products, innovator biotech leaders can benefit from working with CDMOs that have expertise in developing both drug substance and product and can be a single development partner across pre-clinical, clinical and commercial production.

    Considerations for Developing HPAPI Drug Substance
    In any clinical development, whether early or late phase, the first challenge is to ensure sufficient quantity of the drug substance (active pharmaceutical ingredient; API) to cover future clinical phases. However, a pre-clinical manufacturing process to make drug substances is often quite different from what is used in later clinical phases, where the drug maker’s focus shifts to yield improvement and robust manufacturing elements to drive cost efficiencies.

    More mature pharmaceutical companies have learned how to balance the elements of quality, time and cost. However, for the smaller companies that hold a large part of all INDs, such balance may be under-developed. CDMOs can play a pivotal role, but the highly fragmented outsourcing market can make it difficult to differentiate the experienced from the less experienced. The following critical parameters covering drug substance development experience and expertise should be considered when choosing a CDMO partner to manage shortened development timelines for HPAPI products:
    • Manufacturing scale: Manufacturing scale should factor in not only immediate needs, but also what will be needed in the future when production scales up. Scale issues can lead to manufacturing re-validation and related regulatory changes, thereby delaying the programs into clinic and market and also adding costs. Biotech companies should look for a CDMO that will, early on during clinical development, consider and propose phase-appropriate manufacturing scales that reflect both current needs and future growth.
    • Quality regime: The approach to quality control must be suitable for early-phase work, as well as continued into later clinical or commercial phases—requiring the ability to validate, document, and stay in compliance with overall policies. The CDMO must be in a position to play an active role in guiding their customer and provide a sustainable phase-appropriate quality approach to the clinic and to the market (including Quality by Design).
    • Manufacturing acumen: In many cases, manufacturing inefficiencies are adequate for early stage work but are carried forward too long and negatively impact timelines and costs. If manufacturing inefficiencies are carried throughout clinical development, changes in process chemistry, process parameters, intermediate or product specifications can no longer be implemented without substantial change to regulatory documentation (meaning that related studies that need to be completed), resulting in longer timelines and higher costs upon progressing the program to commercialization. Well-seasoned, experienced CDMOs recommend process improvements when these can still be implemented safely and easily.  Such partners remain critical of the process performance, robustness and quality as the program progresses into larger clinical studies.
    • Containment: When considering Highly Potent APIs (HPAPIs), it must be taken into account that containment solutions are often designed for specific situations in the manufacturing process. As companies need to remain compliant and ensure the safety of their employees, a change in scale, approach or unit operations (e.g., adding starting materials to the reactors) may require a change in the required containment solution. Insufficient experience with containment or insufficient attention to containment requirements during initial technical transfer of a program (e.g., change from small filter dryer to a larger centrifuge) may result in changes to unit operations, necessitating a regulatory update. Many CDMOs have increased investments in HPAPI capabilities and claim extensive expertise; however, it is important for biopharma companies to identify potential outsourcing partners that have implemented containment principles and hardware appropriately to ensure efficient technical transfer and manufacturing implementation timelines.
    When looking at the HPAPI product category, a key component is the drug linkers or payloads for antibody drug conjugates (ADCs). This component is growing particularly fast and is often associated with accelerated pathways, sometimes even jumping clinical phases. With the ADC market expected to grow around 30% until 2024,5 the “need for speed” is even more crucial and the challenge of finding a CDMO with the real long-term experience across high potency small molecules, large-molecule biologics (monoclonal antibody and conjugation) and the final product are scarce.6 Experience with high-potency handling, scale-ability, robustness and a track record of quality and delivery are key differentiators that tend to play an even more pronounced role in the combined technologies for ADCs than when a purely small molecule-oriented chemical experience is required.

    Lacking expertise and resources related to the areas above may mean more complications, higher costs, lower quality, additional regulatory filings and result in overall a longer drug development timeline overall and slower time to market entry—all outcomes that biotech innovators want to avoid. When innovator companies partner with CDMOs that have substantial experience in the HPAPI environment—not just investments in equipment and technology—they may stand to achieve shorter production timelines.

    CDMO Qualities to Aid Drug Product Development
    Following HPAPI drug substance production, when considering the development and manufacturing of drug product intermediates (DPI) and drug products (DP), drug developers stand to gain from working with CDMOs that have demonstrated expertise in DPI and DP development and can help find answers to the following questions:
    • Formulation technology: Has the formulation problem statement been adequately defined? What formulation approach is best to meet the target product profile? Is the product’s bioavailability sufficient? If bioavailability enhancement is required what technologies are available and how can they be rationally chosen?
    • Enabling technology: What enabling technology and/or specialized processing is required? Is phase-appropriate processing in place for non-cGMP feasibility and cGMP clinical manufacture? Is there a line-of-sight to commercial manufacture?
    • Devices: What special devices are required for patients to use the drugs? What is the impact on the formulation approach and/or dosage form?
    • Drug product supply: Can product supply be supported in situations where market demand increases or decreases rapidly (e.g. obtaining accelerated approval, market introduction and approval for additional indications)?
    More mature CDMOs will have capabilities to run short feasibility studies relatively early in clinical development (preferably before First-in-Human testing), selecting the best answers to the questions above early in the program and potentially saving time in the long run. For example, with feasibility testing one can tell whether a candidate’s insufficient clinical effect is caused by the candidate itself or by a sub-optimal or inappropriate formulation. This process can help avoid abandoning candidates that could have been optimized with a different formulation approach, allowing for more informed decision on whether to halt, terminate or progress candidates through the pipeline. Especially with increasing speed from concept to the market, the pressure to “Fail Fast” (or fail appropriately) has increased. Choosing a CDMO with the proper drug product intermediate, e.g. a spray dried dispersion, and drug product expertise can help companies make those decisions more effectively.

    Benefits of Working with a Single Integrated CDMO Partner
    Rapidly developing a HPAPI product for clinical trials – with an eye to commercial development in the future – involves expertise across the drug substance-drug product spectrum. Traditionally, many pharmaceutical innovators have worked with various CDMOs for different parts of the development process, receiving the drug substance from one and running the required analyses before handing off to a different drug product manufacturer. Each partner in this value chain will again sample, test and release the incoming product before further processing (e.g., to avoid liability issues), thus creating redundant activities that lengthen development timelines.

    But many questions and issues cross between different stages of the process:
    • What packaging and enabling technologies are best to move the drug substance to formulation?
    • How can we organize a consistent quality control and quality assurance mechanism to avoid full retesting at each step of the value chain?
    • How do we avoid liability discussions between different stages?
    • How do we anticipate changes in schedules and timelines?
    • How do we optimize the ease of collaboration over the entire value chain?

    The most effective way to address these questions may be holistically, rather than at any one point in the value chain. As such, it may be beneficial to work with as few partners as possible across the value chain, in order to save complexity, effort, time and costs. The ideal situation may be one integrated partner, with all activities managed by one overall harmonized quality system governing all product transfers between sites, idealized packaging arrangements between drug substance and drug product (allowing coordination in packaging and containment connections), smooth handovers between production stages (no excess testing required and ideally drug substance can be used for formulation without testing based on its Certificate of Analysis, and similar for drug product towards final packing), and substantial reduction of shipping timelines. A single CDMO may also have different production stages housed at a single site, removing the need for shipping and creating further advantages in terms of efficiency.

    Selecting the Right Partner
    HPAPI products continue to become more advanced and widely used, especially in oncology treatments. Accelerated regulatory pathways are also increasingly utilized to better ensure that new therapies are rapidly advanced. Managing shortened timelines from concept to commercialization will continue to be a top priority for pharma and biotech players. CDMOs can play a pivotal role bringing these products to clinic and to market so patients around the world can experience their benefits.

    When differentiating between collaboration partners, one should evaluate technical expertise based on specific programs and visit the candidate CDMO organization at the facility where the program will be performed. For some smaller CDMOs that means visiting one building, while for others it will mean visiting an entire site with several facilities in one location, or facilities within a broader site network. Extensive interviews with CDMO site management and tours of their laboratories and facilities will help ensure that the right development and manufacturing partner is chosen. 

    References
    1. Citeline and internal Lonza Market Analysis
    2. A. Mullard, “The Drugmaker’s Guide to the Galaxy”, Nature, September 2017, 549, p445-447.
    3. “AI-designed drugs to enter human clinical trials for the first time”, M. Murgia, Financial Times, January-31, 2020
    4. K. Sharma (FDA), “CDER New Drugs Program: 2019 Update”, FDA/CMS Summit, December-3, 1029
    5. Citeline and internal Lonza Market Analysis.
    6. Lonza has more than 20 years of experience in handling high potency programs and a proven track record of over 11 years in Antibody Drug Conjugate programs. Lonza has supported over 30% of all accelerated programs in the past 5 years and Lonza is the selected manufacturing partner for the majority of approved ADCs: See video on youtube: https://www.youtube.com/watch?v=KkAKgU2A6qo


    Dr. Maurits Janssen is Head of Commercial Development, API Development & Manufacturing at Lonza Pharma & Biotech. He has experience progressing a broad portfolio of technologies in cGMP custom manufacturing from clinical into commercial phase, including chemistry (APIs, highly potent, cytotoxic, peptides and bioconjugates) and biotechnology (mammalian, microbial, antibody drug conjugates, cell therapy and viral therapeutics). Dr. Janssen is based in the company’s headquarters in Basel, Switzerland.

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Virtual Clinical Trials: The Future Of Dermatology Studies
    Breaking News
    • Global Biosciences Co. Selects ValGenesis VLMS
    • Eisai Appoints Chief Clinical Officer of Oncology Biz
    • Nexelis Acquires GSK Vax Lab in Marburg
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ingredient Manufacturers Discuss the E-Sports Market
    Euromonitor Names Top Ten Trends for 2021
    Study Highlights Differences Between EPA's and DHA's Effect on Sleep
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Eitan Medical Receives FDA Clearance for Sapphire Infusion System
    Researchers Successfully ‘Fine Tune’ New Thermoplastic Biomaterial
    RSIP Vision Announces Versatile Medical Image Segmentation Tool
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Global Biosciences Co. Selects ValGenesis VLMS
    Eisai Appoints Chief Clinical Officer of Oncology Biz
    Nexelis Acquires GSK Vax Lab in Marburg
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Top Beauty Brands in the World—And Most Loved Fragrances
    P&G Reports Q2 Results
    A Lacquering Technique Makes Very Good Girl by Carolina Herrera Shine
    Happi

    Latest Breaking News From Happi

    Flow Launches Collagen Waters
    David Stanko Joins JPMS
    Ross Introduces Double Cone Tumble Blender
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Domino grows installation and service teams
    ABG keeps pace with demand with recruitment drive
    Acucote expands FSC-certified portfolio
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    First Quality Launches Incognito by Prevail
    Essity Launches Reusable Underwear Product
    Honeywell Delivered 225 Million Masks in December
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    DJO Acquires Trilliant Surgical
    FDA Breakthrough Device Designation Granted to Spiderwort's Spinal Cord Technology
    Bioventus Appoints SVP of Operations
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login